Surrozen reports Q2 2026 results; IND for SZN-8141 planned by Q3 end; PTAB denies Merck petition

Surrozen, Inc./DE

Planned IND submission for SZN-8141 in DME by end of Q3 2026; DUET Phase 1b/2a to start by year-end 2026 with initial data in H2 2027.
PTAB denied Merck's post-grant review petition challenging Surrozen's U.S. Patent No. 12,297,278, reinforcing IP position.
Boehringer Ingelheim milestone triggered $5.0M collaboration revenue in Q2 2026 (vs $0 in Q2 2025).
Cash and cash equivalents $102.0M as of June 30, 2026, down from $106.9M as of March 31, 2026.
Net income $50.2M (including $59.6M non-cash gains) vs $39.7M (including $47.6M non-cash gains) in Q2 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.